Company Profile

Company strategy

DelSiTech is poised to become, within the coming few years, a significant player in the controlled release supergeneric product markets with a first-in-class market leader product for sale in the major global market areas. In addition, DelSiTech aims to become the partner of choice for biotech and pharma companies seeking for the best solution for their delivery needs.

 

The Company strategy is to 1) Sell and license its biodegradable silica based drug delivery technology to biotech and pharma industry customers by providing service for fee, 2) Develop and commercialize the first in-house controlled release drug product for significant unmet medica land commercial need by the end of 2016, and 3) Explore and identify other business opportunities of the silica technology with significant market potential to provide a continuous flow of novel  products in the future.